For the readers interested in the stock health of Puma Biotechnology Inc. (PBYI). It is currently valued at $4.50. When the transactions were called off in the previous session, Stock hit the highs of $4.60, after setting-off with the price of $3.75. Company’s stock value dipped to $3.7379 during the trading on the day. When the trading was stopped its value was $3.75.Recently in News on November 3, 2022, Puma Biotechnology Reports Third Quarter 2022 Financial Results. Raises FY 2022 NERLYNX Net Product Revenue Guidance. You can read further details here
Puma Biotechnology Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $4.60 on 11/21/22, with the lowest value was $1.60 for the same time period, recorded on 05/12/22.
Puma Biotechnology Inc. (PBYI) full year performance was 31.58%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Puma Biotechnology Inc. shares are logging 10.57% during the 52-week period from high price, and 181.25% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.60 and $4.07.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1322034 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Puma Biotechnology Inc. (PBYI) recorded performance in the market was 48.03%, having the revenues showcasing 41.51% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 193.91M, as it employees total of 196 workers.
Market experts do have their say about Puma Biotechnology Inc. (PBYI)
During the last month, 0 analysts gave the Puma Biotechnology Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 2.82, with a change in the price was noted +1.65. In a similar fashion, Puma Biotechnology Inc. posted a movement of +57.89% for the period of last 100 days, recording 229,914 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for PBYI is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 4.41.
Technical breakdown of Puma Biotechnology Inc. (PBYI)
Raw Stochastic average of Puma Biotechnology Inc. in the period of last 50 days is set at 96.03%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 96.03%. In the last 20 days, the company’s Stochastic %K was 91.97% and its Stochastic %D was recorded 81.93%.
Bearing in mind the latest performance of Puma Biotechnology Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 48.03%. Additionally, trading for the stock in the period of the last six months notably improved by 134.38%, alongside a boost of 31.58% for the period of the last 12 months. The shares increased approximately by 24.65% in the 7-day charts and went down by 104.55% in the period of the last 30 days. Common stock shares were driven by 41.51% during last recorded quarter.